Additional Value of 2-[18F]FDG PET/CT Comparing to MRI in Treatment Approach of Anal Cancer Patients
| Autor: | Reza Vali, Alexander Kupferthaler, Reyhaneh Manafi-Farid, Georg Gruber, Helwig Valentin Wundsam, Clemens Venhoda, Hans Geinitz, Ali Beheshti, C. Track, Werner Langsteger, Mohsen Beheshti |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
anal cancer
PET/CT lcsh:Medicine Standardized uptake value 2-[18F] FDG management change Article 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine medicine Anal cancer Stage (cooking) Radiation treatment planning PET-CT medicine.diagnostic_test business.industry lcsh:R Magnetic resonance imaging General Medicine medicine.disease Primary tumor Positron emission tomography 030220 oncology & carcinogenesis prognosis business Nuclear medicine MRI |
| Zdroj: | Journal of Clinical Medicine Volume 9 Issue 9 Journal of Clinical Medicine, Vol 9, Iss 2715, p 2715 (2020) |
| ISSN: | 2077-0383 |
| Popis: | Accurate staging and treatment planning are imperative for precise management in Anal Cancer (ACa) patients. We aimed to evaluate the additive and prognostic value of pre-treatment 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (2-[18F]FDG PET/CT) in the staging and management of ACa compared to magnetic resonance imaging (MRI). This retrospective study was conducted on 54 patients. Pre-treatment 2-[18F]FDG PET/CT studies and MRI reports were compared considering the primary tumor, pelvic lymph nodes, and metastatic lesions. The impact of 2-[18F]FDG PET/CT in the management and its prognostic value, using maximum standardized uptake value (SUVmax), were assessed. Discordant findings were found in 46.3% of patients (5 in T 1 in T and N 18 in N and 1 in M stage). 2-[18F]FDG PET/CT resulted in up-staging in 9.26% and down-staging in 3.7% of patients. Perirectal lymph nodes were metabolically inactive in 12.9% of patients. Moreover, 2-[18F]FDG PET/CT resulted in management change in 24.1% of patients. Finally, SUVmax provided no prognostic value. 2-[18F]FDG PET/CT altered staging and management in a sizable number of patients in this study, and supports a need for a change in guidelines for it to be used as a routine complementary test in the initial management of ACa. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|